T1	Participants 461 490	advanced solid tumor patients
T2	Participants 608 625	both study groups
T3	Participants 853 888	, individuals varied in BP response
T4	Participants 1131 1217	Patients have intrinsic differences in sensitivity to sorafenib's BP-elevating effects
